Pulmonary Cell News Volume 9.44 | Nov 12 2020

May 12, 2022

2020-12-11 | PULCN 9.44

Pulmonary Cell News by STEMCELL Technologies

Vol. 9.44 – 12 November, 2020

TOP STORY

mTORC1
Activation in Lung Mesenchyme Drives Sex- and Age-Dependent Pulmonary Structure and Function Decline

Investigators profile a lymphangioleiomyomatosis (LAM) lung compared to an age- and sex-matched healthy control lung as a hypothesis-generating approach to identify cell subtypes that are specific to LAM.
[Nature Communications]

Full Article

Tools and products for your COVID-19 research.

PUBLICATIONSRanked by the impact factor of the journal

Pulmonary Surfactant Inhibition of Nanoparticle Uptake by Alveolar Epithelial Cells

Researchers investigated the role of a surfactant as a protective physical barrier by modeling the interactions using silica-Curosurf-alveolar epithelial cell system in vitro.
[Scientific Reports]

Full Article

Paracoccidioides brasiliensis
Downmodulates α3 Integrin Levels in Human Lung Epithelial Cells in a TLR2-Dependent Manner

Scientists showed that, after 24 hour post-infection with P. brasiliensis, A549 lung epithelial cells presented higher TLR2 levels, which was important for IL-8 secretion.
[Scientific Reports]

Full Article

In
Well-Differentiated Primary Human Bronchial Epithelial Cells, TGF-β1 and TGF-β2 Induce Expression of Furin

Investigators assessed the suitability of primary human bronchial epithelial cells maintained in air-liquid interface as an experimental system for studying SARS-CoV-2 infection in vitro.
[American Journal of Physiology-Lung Cellular and Molecular Physiology]

Abstract

LUNG CANCER

The Mechanism of m⁶A
Methyltransferase METTL3-Mediated Autophagy in Reversing Gefitinib Resistance in NSCLC Cells by β-Elemene

Scientists found that N⁶-methyladenosine (m⁶A) methyltransferase METTL3-mediated autophagy played an important role in reversing gefitinib resistance by β-elemene in NSCLC cells.
[Cell Death & Disease]

Full Article

Induction
of NEDD8-Conjugating Enzyme E2 UBE2F by Platinum Protects Lung Cancer Cells from Apoptosis and Confers to Platinum-Insensitivity

Researchers report that the upregulation of the NEDD8-conjugating enzyme UBE2F was an important way for lung cancer cells to escape platinum-induced cell apoptosis, which conferred to insensitivity to platinum-based chemotherapy.
[Cell Death & Disease]

Full Article

AXL
Inhibition Induces DNA Damage and Replication Stress in Non-Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors

The authors showed that BGB324, a selective small-molecule AXL inhibitor, caused DNA damage and induced replication stress, indicated by ATR/CHK1 phosphorylation, more significantly in TP53-deficient NSCLC cell lines.
[Molecular Cancer Research]

Abstract

Inhibition
of Histamine Receptor H3 Suppresses the Growth and Metastasis of Human Non-Small Cell Lung Cancer Cells via Inhibiting PI3K/Akt/mTOR and MEK/ERK Signaling Pathways and Blocking EMT

In five human NSCLC cell lines tested, histamine receptor H3 (Hrh3) was significantly upregulated. In NSCLC cell lines H1975, H460, and A549, Hrh3 antagonist ciproxifan exerted moderate and concentration-dependent inhibition on the cell growth and induced apoptosis, whereas its agonist RAMH reversed these effects.
[Acta Pharmacologica Sinica]

Abstract

Cancer
Type‑SLCO1B3 Promotes Epithelial‑Mesenchymal Transition Resulting in the Tumor Progression of Non‑Small Cell Lung Cancer

RNAi‑mediated knockdown of Ct‑SLCO1B3 inhibited in vitro anchorage‑independent cell growth, cell migration, and in vivo tumor growth of A549 cells.
[Oncology Reports]

Abstract

Amplified
LncRNA PVT1 Promotes Lung Cancer Proliferation and Metastasis by Facilitating VEGFC Expression

Elevated levels of plasmacytoma variant translocation 1 (PVT1) promoted lung cancer cell proliferation and metastasis, both in vitro and in vivo. Mechanistically, scientists found that PVT1 competed endogenously with miR-128 in the regulation of vascular endothelial growth factor C expression, which was significantly associated with an unfavorable prognosis in lung cancer.
[Biochemistry and Cell Biology]

Abstract

Virtual Conference Exhibition: Organoids

REVIEWS

Human
Air-Liquid-Interface Organotypic Airway Tissue Models Derived from Primary Tracheobronchial Epithelial Cells—Overview and Perspectives

Human air-liquid-interface organotypic airway tissue models derived from primary tracheobronchial epithelial cells have in vivo–like structure and functions when they are fully differentiated.
[in Vitro Cellular & Developmental Biology-Animal]

Full Article

INDUSTRY AND POLICY NEWS

Puma
Biotechnology Announces Interim Results from the Phase II SUMMIT Trial of Neratinib for EGFR Exon 18 Mutated, Metastatic Non-Small Cell Lung Cancer

Puma Biotechnology, Inc. announced interim results from the ongoing SUMMIT trial of neratinib in the cohort of metastatic NSCLC patients with epidermal growth factor exon 18 mutations that has been previously treated with an EGFR targeted tyrosine kinase inhibitor.
[Puma Biotechnology, Inc.]

Press Release

Merck Announces KEYNOTE-598 Trial Evaluating KEYTRUDA^® (Pembrolizumab) in Combination with Ipilimumab versus KEYTRUDA Monotherapy in Certain Patients With Metastatic Non-Small Cell Lung Cancer to Stop for Futility and Patients to Discontinue Ipilimumab

Merck announced that it will be stopping KEYNOTE-598, a Phase III trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with ipilimumab, compared with KEYTRUDA monotherapy, for the first-line treatment of patients with metastatic NSCLC whose tumors express PD-L1 with no EGFR or ALK genomic tumor aberrations.
[Merck & Co., Inc.]

Press Release

Bristol Myers Squibb Receives European Commission Approval for Opdivo (Nivolumab) plus Yervoy (Ipilimumab) with Two Cycles of Chemotherapy for First-Line Treatment of Metastatic Non-Small Cell Lung Cancer

Bristol Myers Squibb announced that the European Commission has approved Opdivo plus Yervoy with two cycles of platinum-based chemotherapy for the first-line treatment of adult patients with metastatic NSCLC whose tumors have no sensitizing epidermal growth factor receptor mutation or anaplastic lymphoma kinase translocation.
[Bristol Myers Squibb]

Press Release

FEATURED EVENT

mTORC1
Activation in Lung Mesenchyme Drives Sex- and Age-Dependent Pulmonary Structure and Function Decline

Pulmonary Surfactant Inhibition of Nanoparticle Uptake by Alveolar Epithelial Cells

Paracoccidioides brasiliensis
Downmodulates α3 Integrin Levels in Human Lung Epithelial Cells in a TLR2-Dependent Manner

In
Well-Differentiated Primary Human Bronchial Epithelial Cells, TGF-β1 and TGF-β2 Induce Expression of Furin

The Mechanism of m⁶A
Methyltransferase METTL3-Mediated Autophagy in Reversing Gefitinib Resistance in NSCLC Cells by β-Elemene

Induction
of NEDD8-Conjugating Enzyme E2 UBE2F by Platinum Protects Lung Cancer Cells from Apoptosis and Confers to Platinum-Insensitivity

AXL
Inhibition Induces DNA Damage and Replication Stress in Non-Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors

Inhibition
of Histamine Receptor H3 Suppresses the Growth and Metastasis of Human Non-Small Cell Lung Cancer Cells via Inhibiting PI3K/Akt/mTOR and MEK/ERK Signaling Pathways and Blocking EMT

Cancer
Type‑SLCO1B3 Promotes Epithelial‑Mesenchymal Transition Resulting in the Tumor Progression of Non‑Small Cell Lung Cancer

Amplified
LncRNA PVT1 Promotes Lung Cancer Proliferation and Metastasis by Facilitating VEGFC Expression

Human
Air-Liquid-Interface Organotypic Airway Tissue Models Derived from Primary Tracheobronchial Epithelial Cells—Overview and Perspectives

Puma
Biotechnology Announces Interim Results from the Phase II SUMMIT Trial of Neratinib for EGFR Exon 18 Mutated, Metastatic Non-Small Cell Lung Cancer

Merck Announces KEYNOTE-598 Trial Evaluating KEYTRUDA^® (Pembrolizumab) in Combination with Ipilimumab versus KEYTRUDA Monotherapy in Certain Patients With Metastatic Non-Small Cell Lung Cancer to Stop for Futility and Patients to Discontinue Ipilimumab

Bristol Myers Squibb Receives European Commission Approval for Opdivo (Nivolumab) plus Yervoy (Ipilimumab) with Two Cycles of Chemotherapy for First-Line Treatment of Metastatic Non-Small Cell Lung Cancer

Cell Symposia: 20 Years of the Human Genome: From Sequence to Substance

> See All Events

Postdoctoral Research Position and PhD Position – Cardiovascular and Lung Diseases

Faculty
Position – Oncology & Lung Cancer

Postdoctoral
Fellow – Parenchymal/Vascular Lung Disease

Assistant
Professor – Respirologist

Postdoctoral Fellow – Pharmacogenomics and Integrative Genomics

Postdoctoral
Research Associate – Acute Lung Injury

> See All Jobs